Alnylam Pharmaceuticals (ALNY) Projected to Post Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, July 31st. Analysts expect Alnylam Pharmaceuticals to post earnings of ($0.05) per share and revenue of $633.54 million for the quarter. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the company earned ($0.16) EPS. The company's revenue for the quarter was up 20.2% on a year-over-year basis. On average, analysts expect Alnylam Pharmaceuticals to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Up 0.2%

Shares of Alnylam Pharmaceuticals stock traded up $0.81 on Friday, reaching $328.81. 666,674 shares of the company were exchanged, compared to its average volume of 894,988. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $333.70. The company has a market capitalization of $42.87 billion, a price-to-earnings ratio of -157.33 and a beta of 0.23. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The company has a 50-day moving average of $310.69 and a 200 day moving average of $274.03.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This represents a 28.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

An institutional investor recently bought a new position in Alnylam Pharmaceuticals stock. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,032 shares of the biopharmaceutical company's stock, valued at approximately $243,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Chardan Capital upped their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Stifel Nicolaus upped their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. BMO Capital Markets upped their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 24th. Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. Finally, Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $347.75.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.